GT Biopharma (GTBP) Cash & Equivalents (2010 - 2026)

GT Biopharma (GTBP) has reported Cash & Equivalents for 17 consecutive years, with $7.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 218.18% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 218.18% YoY), while the FY2025 annual figure was $3.9 million, up 2.63% from the prior year.
• Cash & Equivalents advanced to $7.0 million in Q1 2026 per GTBP's latest filing, from $3.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $16.0 million in Q3 2023 and bottomed at $1.1 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $4.9 million across 5 years, with a median of $3.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 86.33% — and 2023, when it surged 549.09%.
• GT Biopharma's Cash & Equivalents stood at $5.7 million in 2022, then sank by 80.98% to $1.1 million in 2023, then surged by 252.18% to $3.8 million in 2024, then gained by 2.63% to $3.9 million in 2025, then surged by 79.49% to $7.0 million in 2026.
• Business Quant data shows GTBP's Cash & Equivalents at $7.0 million in Q1 2026, $3.9 million in Q4 2025, and $2.1 million in Q3 2025.